Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
Thomas Powles(Queen Mary University of London), Petros Grivas(Seattle Cancer Care Alliance), John A. Blake-Haskins(Inserm), Nuno Costa(Inserm), Norihiko Tsuchiya(Yamagata University), Yohann Loriot(Institut Gustave Roussy), Jeanny B. Aragon‐Ching(Inova Fairfax Hospital), Howard Gurney(Radboud University Nijmegen), Srikala S. Sridhar(Princess Margaret Cancer Centre), Bo Huang(Inserm), Begoña P. Valderrama(Inserm), Daniel P. Petrylak(Yale University), Se Hoon Park(Samsung Medical Center), Haralabos P. Kalofonos(University of Patras), Claudia Caserta(Inserm), Camilla Fowst(Inserm), Craig B. Davis(National Institutes of Health), Siniša Radulović(Inserm), Joaquim Bellmunt(Dana-Farber Cancer Institute), Wim Demey(Inserm), Evgeny Kopyltsov(Inserm), Anders Ullén(Inserm), Jing Wang(NYU Langone Health), Alessandra di Pietro(Inserm), Cora N. Sternberg(Cornell University), Robert J Laliberte(Inserm), Éric Voog(Centre Jean Bernard)
Cited by 1,474
Related Papers
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Identification of a major co-receptor for primary isolates of HIV-1
|Nature|1996|3.7k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k